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Abstract 
Purpose: Patients with type 2 diabetes mellitus (T2DM) have impaired ketogenesis due to high 
serum insulin and low growth hormone levels. Evidence exists that ketone bodies might improve 
kidney and cardiac function. In theory, improved ketogenesis in diabetics may have positive 
effects. We aimed to assess the impact of diabetic ketosis (DK) on all-cause mortality in patients 
with T2DM presenting with hyperglycemic crisis. 
Methods: We analyzed 486 patients with DK and 486 age- and sex-matched patients with non-
ketotic hyperglycemia (NKH) presenting to the emergency department. Cox proportional hazard 
models were used to analyze the link between patient characteristics and mortality. 
Results: During an observation time of 33.4 months, death of any cause occurred in 40.9% of 
the NKH group and 30.2% of the DK group (hazard ratio in the DK group, 0.63; 95% confidence 
interval 0.48 - 0.82; P = 0.0005). Patients with DK had a lower incidence of symptomatic heart 
failure and had improved renal function. They used less furosemide and antihypertensive drugs, 
more metformin and lower insulin doses, all of which was independently associated with 
decreased mortality. Plasma glucose and glycated hemoglobin levels were similar in both groups. 
Conclusions: Patients with hyperglycemic crisis and DK have decreased all-cause mortality 
when compared to those with NKH. DK might be a compensatory mechanism rather than a 
complication in patients with hyperglycemic crises, but further prospective studies are warranted.    
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Introduction 
Type 2 diabetes mellitus (T2DM) is associated with impaired ketogenesis [1]. Even non-diabetic 
obese subjects tend to have lower serum non-esterified fatty acids and ketone bodies [2]. 
Hyperinsulinemia seems to directly suppress ketogenesis in the liver, but growth hormone and 
glucagon may have an important role in ketogenesis [3–5]. On the other hand, some patients with 
clinical features of T2DM may develop diabetic ketoacidosis. This is a poorly defined and 
elusive clinical entity also known as ketosis-prone type 2 diabetes [6]. It occurs predominantly in 
obese middle-aged men of Hispanic and Afro-American ethnicity and autoimmunity markers are 
usually absent [6]. Whether an incidental finding of diabetic ketosis (DK) without acidosis in 
Caucasians could be referred to as ketosis-prone T2DM is unknown. Similarly, the clinical 
significance of DK in patients presenting to the emergency departments with hyperglycemic 
crises is unknown and treatment guidelines for such patients are lacking. 
On the other hand, there is an ongoing debate on the EMPA-REG OUTCOME trial results. 
Empagliflozin, an inhibitor of sodium–glucose cotransporter 2 (SGLT2) was the first anti-
diabetic drug that reduced mortality in patients with type 2 diabetes mellitus (T2DM) with high 
cardiovascular risk factors [7]. The underlying mechanisms are being speculated, but neither one 
hypothesis included ketone bodies. SGLT2 inhibitors induce profound glycosuria, and 
consequently, increased ketogenesis [8]. We aimed to assess the role of ketone bodies in patients 
with T2DM. We analyzed clinical and laboratory characteristics and all-cause mortality rates in 
patients with T2DM presenting to our emergency department with diabetic ketosis (DK) and 
non-ketotic hyperglycemia (NKH).  
 
 
Methods 
Patients  
This was a single-center, retrospective, cross-sectional study performed in the emergency 
department of a teaching hospital. We reviewed electronic charts from all patients with plasma 
glucose (PG) > 13.9 mmol/L at admission between January 1
st
 2010 and December 31
st
 2014. 
DK was defined as PG >13.9 mmol/L, ketonuria >2+ and a capillary bicarbonate level >18 
mmol/L or capillary blood pH >7.30. Patients with PG >13.9 mmol/L and undetectable ketonuria 
(<1+) were classified as non-ketotic hyperglycemia (NKH). Patients were considered to have 
T2DM if they were not diagnosed with T1DM prior to or after admission or if they were older 
than 40 years at diagnosis, because T2DM in young adults is rare in our population. Patients 
younger than 40 years, patients diagnosed with type 1 diabetes mellitus and patients with 
malignant diseases were excluded. 
Patient data including past medical history, comorbidities, medication and physical examination 
was obtained from the emergency department charts. Diabetes-specific data (glycated 
hemoglobin, body mass index, renal function) was obtained from different institutional 
electronic registries and was only analyzed in patients that attended a regular diabetologist visit 
six months prior or six months after admission. Mortality data was obtained from the Croatian 
Department of Public Health.  
 
Statistical analyses 
Patient characteristics were assessed using descriptive statistics presented as a mean with 
standard deviation. Independent continuous variables were compared using the t-test or Mann-
Whitney test when appropriate and categorical variables using the Chi square test. Cox 
proportional hazard models were used to analyze the link between patient characteristics and 
mortality, and to adjust for potential confounding factors. Backward conditional stepwise 
approach was used to determine variables independently associated with survival. P values <0.05 
were considered significant. The statistical analysis was done using SPSS Version 20.0. 
 
 
Results  
Among 103,563 admissions over the five-year period, there were 5,088 admissions in which 
patients had PG >13.9 mmol/L. Acid-base status or urine analysis was missing in 1,679 
admissions and these patients were excluded from further analyses. Among 3,409 admissions, 
we observed 630 episodes of DK in 520 patients, 215 episodes of DKA in 165 patients, and 
2,562 episodes of NKH in 2,041 patients. Only 8.5% (44) of patients with DK had the diagnosis 
of type 1 diabetes mellitus and they were excluded from the study. First admissions of 486 
patients with DK and 486 age- and sex-matched patients with NKH were included in the study. 
There were no differences in age and gender between the groups, but patients in the DK group 
had a slightly shorter duration of diabetes (Table 1).  During an observation time of 33.4 months, 
death of any cause occurred in 199 patients (40.9%) in the NKH group and in 147 (30.2%) in the 
DK group (hazard ratio in the DK group, 0.63; 95% confidence interval, 0.48 to 0.82; P = 
0.0005). Mortality risk was even lower after adjustment for duration of diabetes (HR 0.442, 95% 
CI 0.30-0.65, P<0.001) (Figure 1). All 46 patients in the NKH group who were readmitted had 
NKH at their next visit. Similarly, 91.0% (40/44) of patients with DK, had DK on their next visit. 
Patient characteristics are presented in table 1. Patients with DK had higher hospitalization rates, 
a higher incidence of newly diagnosed T2DM and acute coronary syndromes, but lower 
incidence of symptomatic heart failure and cardiac arrhythmias. The duration of the leading 
symptom at admission was longer in patients with NKH. Dyspnea was more frequent in the 
NKH group, while vomiting was more frequent in DK group. Patients with DK had higher 
estimated hemoglobin, estimated glomerular filtration rate (eGFR), capillary pH and bicarbonate, 
leukocytes and C-reactive protein levels, and lower potassium levels. Plasma glucose at 
admission and HbA1c six months prior or after the admission were similar in both groups. 
Patients with DK used less furosemide, calcium channel blockers, beta-blockers and less 
antihypertensive agents despite the fact that both groups had similar blood pressure at admission. 
Patients with DK used metformin more frequently and needed lower insulin doses to achieve 
similar HbA1c levels. Interestingly, the association between DK and mortality diminished after 
adjustment for metformin use. Patients with DK had lower serum hemoglobin and potassium 
levels, higher leucocytes, C-reactive protein and higher estimated glomerular filtration rate 
(eGFR). However, in backward conditional stepwise analysis, only advanced age (HR 1.05, 95% 
CI 1.01 - 1.09, P=0.011), male gender (HR 5.744, 95% CI 1.73 - 19.08, P=0.004), eGFR (HR 
0.98, 95% CI 0.97 - 0.99, P=0.004) and symptomatic heart failure (HR 6.48, 95% CI 2.17 - 
19.34, P=0.001) were independently associated with mortality. In a stepwise multivariate 
analysis that included all medication, mortality was increased in patients taking sulfonylureas 
(HR 1.89, 95% CI 1.30-2.76, P=0.001), insulin (HR 1.54, 95% CI 1.03-2.31, P=0.037), 
furosemide (HR 1.60, 95% CI 1.07-2.41, P=0.023), calcium antagonists (HR 1.43, 95% CI 1.00 
– 2.05, P=0.049), and decreased in patients taking metformin (HR 0.66, 95% CI 0.44-0.99, 
P=0.043).  
 
 
 Discussion  
To the best of our knowledge, this is the first study that compared survival rates in patients with 
and without DK presenting with hyperglycemic crises.  Similar to our study, previous studies 
have shown high mortality rates after hyperglycemic crises [9], emphasizing the need for 
prevention and proper treatment.  
In patients with T1DM, DK precedes the development of diabetic ketoacidosis and requires 
prompt management and self-monitoring. However, little is known about DK in patients with 
T2DM.  Our study showed that patients with DK have decreased all-cause mortality when 
compared with patients with NKH. Previous studies have shown that patients with T2DM have 
impaired ketogenesis, which is associated with high serum insulin levels which directly suppress 
ketogenesis in the liver [4,5]. High insulin levels also inhibit growth hormone and glucagon 
secretion, both of which may contribute to suppressed ketogenesis [4]. In our study, patients with 
DK used more metformin and required lower insulin doses, both of which may be associated 
with lower serum insulin levels and improved ketogenesis. In a multivariate model that included 
metformin and ketonuria, the link between DK, metformin and survival diminished. This 
suggests that metformin plays important role in improving ketogenesis in patients with T2DM. 
Previous studies also showed decreased mortality in patients taking metformin and increased 
mortality in patients taking sulfonylureas and insulin irrespectively of blood glucose control and 
duration of diabetes [10–12]. Improved ketogenesis can also be attributed to physical activity, 
type of diet, adenosine 5'-monophosphate-activated protein kinase (AMPK) activity and 
expression of the Foxa2 gene [13,14], although these factors were not analyzed in our study.  
Positive ketone bodies can also be attributed to excessive vomiting, which was more common in 
the DK group. 
In terms of the link between ketogenesis and decreased mortality, it is important to mention that 
due to this study’s restrospecive and cross-sectional design, no association means causality, and 
this decreases the strength of any conclusions. Heart failure and kidney disease is the leading 
cause of death in diabetics. In our study, symptomatic heart failure, furosemide use, and 
estimated glomerular filtration rate were independently associated with mortality as well. 
Interestingly, patients with DK had less symptomatic heart failure, used less furosemide and 
antihypertensive drugs and had higher eGFR at admission, when compared with patients with 
NKH. In patients with diabetes, ketone bodies are more efficient fuel sources than glucose since 
insulin is not required for their utilization. Therefore, proper ketogenesis in acute hyperglycemic 
crisis may be lifesaving, because it supplies the myocardium with a sufficient amount of energy. 
Indeed, previous studies have found that hypertrophied and failing hearts shift to ketone body 
utilization [15][16]. Moreover, ketone bodies have protective effects on the kidney and infusion 
of exogenous ketone bodies improves kidney function in healthy subjects and in patients with 
diabetes [17][18][19]. 
In the end, we would like to correlate our results with the results of the EMPA-REG outcome 
trial. SGLT-2 inhibitors are the most potent stimulators of ketogenesis by promoting profound 
glycosuria, carbohydrate depletion, and consequent rise in serum glucagon and decrease in serum 
insulin levels [8]. Several cases of normoglycemic ketoacidosis have been described in patients 
treated with SGLT-2 inhibitors [20]. Empagliflozin was the first anti-diabetic drug that reduced 
mortality in patients with T2DM and high cardiovascular risk factors. Empagliflozin did not 
reduce the incidence of myocardial infarction or stroke, but reduced hospitalization rates for 
heart failure, death from cardiovascular causes, and decreased the progression of kidney disease 
[7,21]. Although our study cannot be directly compared to the EMPA-REG trial, we observed 
that patients with DK and patients treated with empagliflozin had similar outcomes in terms of 
lower heart failure rates and kidney disease. Unfortunately, the EMPA-REG trial did not assess 
dynamics of ketogenesis.  
Our study has several limitations due to its retrospective and cross-sectional design. Ketone body 
status was determined only during the acute hyperglycemic crisis. Patient follow-up and repeated 
ketone body measurement would improve the power of the study. Furthermore, the diagnosis of 
T2DM was based on whether or not the diagnosis of type 1 diabetes mellitus was made prior or 
after the hyperglycemic crisis, and antibody status and beta-cell function were not assessed. 
However, in our Croatian population, T2DM is uncommon in young adults; therefore, we set an 
arbitrary cut-off of 40 years at initial diagnosis to reduce the chances of including patients with 
type 1 diabetes. The fact that both groups had similar body mass index, duration of diabetes and 
proportion of patients requiring insulin therapy suggests that we successfully recruited patients 
with T2DM. 
In conclusion, type 2 diabetic patients with hyperglycemic crisis and DK have decreased all-
cause mortality when compared to those with NKH. As our findings are retrospective and cross-
sectional, further prospective studies are needed to explore the possibility that DK may be a 
protective factor in patients with hyperglycemic crises.  
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Table 1. Differences in anthropometric characteristics, medical history, physical examination and 
laboratory results between patients with non-ketotic hyperglycemia (NKH) and diabetic ketosis 
(DK).  
 
 NKH 
N = 486 
DK 
N = 486 
         P value⃰ 
Age (years) 66.8 ± 12.3 67.1 ± 11.6 0.770 
Male gender n (%) 56.2 (273) 55.1 (268) 0.759 
Duration of diabetes (years) 11.5 ± 9.7 9.8 ± 9.6 0.047 
BMI (kg/m
2) † 30.8 ± 5.9 30.0 ± 6.3 0.234 
Hospitalized n (%) 41.9 (204) 50.5 (238) 0.035 
Readmissions n (%) 9.3 (46) 9.1 (44) 0.961 
Newly diagnosed diabetes n (%) 15.2 (74) 21.6 (105) 0.013 
Reason for admission    
Acute coronary syndrome n (%) 4.7 (23) 16.1 (78) <0.001 
Symptomatic heart failure n (%) 5.8 (28) 0.8 (4) <0.001 
Hyperglycemia n (%) 36.4 (177) 38.9 (189) 0.506 
Symptoms and physical 
examination 
  
 
Weight loss n (%) 11.3 (55) 10.9 (53) 0.961 
Polyuria n (%) 18.7 (91) 23.3 (113) 0.100 
Abdominal pain n (%) 23.3 (113) 27.2 (132) 0.184 
Vomiting n (%) 11.9 (58) 23.1 (112) <0.001 
Dyspnea 19.5 (95) 5.5 (27)  <0.001 
Duration of symptoms (days) 11.9 ± 39.6 5.2 ± 13.7 <0.001 
Systolic blood pressure (mmHg) 141.8 ± 25.1 141.2 ± 25.8 0.815 
Diastolic blood pressure (mmHg) 83.0 ± 13.1 83.2 ± 13.2 0.881 
Heart rate (beats/min) 88.7 ± 21.6 93.1 ± 20.9 0.026 
Sinus rhythm n (%) 80.0 (389) 88.3 (429) <0.001 
Laboratory findings    
Plasma glucose (mmol/L) 20.4 ± 6.4 20.6 ± 6.2 0.517 
HbA1c (%) † 8.5 ± 2.1 8.6 ± 2.2 0.772 
Leucocytes (10
9
/L) 10.9 ± 5.8 11.8 ± 5.3 0.008 
Hemoglobin (g/L) 133.1 ± 23.5 140.0 ± 19.5 <0.001 
eGFR (ml/min) † 73.4 ± 34.9 82.1 ± 34.1 0.023 
Sodium (mmol/L) 134.8 ± 5.4 134.5 ± 4.4 0.312 
Potassium (mmol/L) 4.4 ± 0.7 4.2 ± 0.5 <0.001 
CRP (mg/L) 48.2 ± 82.0 71.4 ± 100.6 <0.001 
pH 7.40 ± 0.10 7.43 ± 0.06 <0.001 
Bicarbonates (mmol/L) 21.2 ± 5.1 22.7 ± 3.7 <0.001 
Medication    
Metformin n (%) 22.8 (111) 34.5 (168) <0.001 
Sulfonylureas n (%) 31.1 (151) 34.8 (169) 0.246 
Insulin n (%) 24.7 (120) 25.1 (122) 0.987 
Insulin dose (units) 57.2 ± 43.8 42.7 ± 19.6 0.004 
Statins 20.2 (98) 18.1 (88) 0.463 
Furosemide n (%) 21.0 (102) 9.5 (46) <0.001 
Thiazides 24.5 (119) 24.3 (118) 1.000 
ACE inhibitors 44.2 (215) 42.2 (205) 0.560 
Beta-blockers 35.6 (173) 19.3 (94) <0.001 
Calcium channel blockers 36.2 (176) 16.7 (81) <0.001 
Number of antihypertensives    
0 28.8 (140) 35.3 (173) 0.023 
1 27.0 (131) 35.8 (174) 0.004 
2 23.9 (116) 20.0 (97) 0.162 
3 15.2 (74) 8.2 (40) 0.001 
4 4.9 (24) 0.6 (3) <0.001 
OAD – oral antidiabetic drugs; eGFR – estimated glomerular filtration rate was calculated with 
Chronic Kidney Disease Epidemiology Collaboration formula; HbA1c – glycated hemoglobin; 
BMI – body mass index; ACE - angiotensin-converting-enzyme 
⃰ continous variables are compared with t-test or Mann-Whitney test when appropriate and 
categorical variables with Chi-square test;  
† analysis performed on 305 subjects with diabetic ketosis and 276 patients with NKH. 
 
Figure 1. Shown are the cumulative hazards of the all-cause mortality adjusted for duration of 
diabetes in patients with non-ketotic hyperglycemia (red line) and diabetic ketosis (blue line). 
Hazard ratios are based on Cox regression analyses. 
 
